These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 27127303)

  • 61. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
    Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A comparative study of adjuvants effects on neonatal plasma cell survival niche in bone marrow and persistence of humoral immune responses.
    Aradottir Pind AA; Thorsdottir S; Magnusdottir GJ; Meinke A; Del Giudice G; Jonsdottir I; Bjarnarson SP
    Front Immunol; 2022; 13():904415. PubMed ID: 35990686
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Toll-like receptor signaling in multiple myeloma cells promotes the expression of pro-survival genes B-cell lymphoma 2 and MYC and modulates the expression of B-cell maturation antigen.
    Tryggestad SS; Roseth IA; Aass KR; Ørning NEH; Mjelle R; Hella H; Standal T
    Front Immunol; 2024; 15():1393906. PubMed ID: 38911853
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The development of a model for the homing of multiple myeloma cells to human bone marrow.
    Urashima M; Chen BP; Chen S; Pinkus GS; Bronson RT; Dedera DA; Hoshi Y; Teoh G; Ogata A; Treon SP; Chauhan D; Anderson KC
    Blood; 1997 Jul; 90(2):754-65. PubMed ID: 9226176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
    Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
    Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
    Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
    Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
    Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
    Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
    Schuh E; Musumeci A; Thaler FS; Laurent S; Ellwart JW; Hohlfeld R; Krug A; Meinl E
    J Immunol; 2017 Apr; 198(8):3081-3088. PubMed ID: 28283566
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.
    Rennert P; Schneider P; Cachero TG; Thompson J; Trabach L; Hertig S; Holler N; Qian F; Mullen C; Strauch K; Browning JL; Ambrose C; Tschopp J
    J Exp Med; 2000 Dec; 192(11):1677-84. PubMed ID: 11104810
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
    An G; Acharya C; Feng X; Wen K; Zhong M; Zhang L; Munshi NC; Qiu L; Tai YT; Anderson KC
    Blood; 2016 Sep; 128(12):1590-603. PubMed ID: 27418644
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA.
    Zheng C; Zhang X; Zhao Z; Hao X; Wei J; Sun J
    Protein Pept Lett; 2017; 24(6):489-494. PubMed ID: 28260502
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.
    Ng YY; Du Z; Zhang X; Chng WJ; Wang S
    Cancer Gene Ther; 2022 May; 29(5):475-483. PubMed ID: 34471234
    [TBL] [Abstract][Full Text] [Related]  

  • 78. B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
    Dogan A; Siegel D; Tran N; Fu A; Fowler J; Belani R; Landgren O
    Blood Cancer J; 2020 Jun; 10(6):73. PubMed ID: 32606424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 80. POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17.
    Zhao C; Inoue J; Imoto I; Otsuki T; Iida S; Ueda R; Inazawa J
    Oncogene; 2008 Jan; 27(1):63-75. PubMed ID: 17621271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.